Ignite Creation Date:
2024-05-05 @ 6:53 PM
Last Modification Date:
2024-10-26 @ 9:38 AM
Study NCT ID:
NCT00562068
Status:
UNKNOWN
Last Update Posted:
2013-08-26
First Post:
2007-11-20
Brief Title:
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I Stage II Stage III or Stage IV Peripheral T-Cell Lymphoma
Sponsor:
Cancer Research UK
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
CDR0000576439
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cancer Research UK
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None